Fundz

Tris Pharma Announces Acquisition Of New, Late-Stage Drug Candidate For Pain

PRIVATEDec 07, 2022

Acquiring Company

Tris Pharma

Acquired Company

Drug Candidate

Monmouth JunctionHealthcarePharmaceutical Manufacturing

Description

Tris Pharma, Inc. ("Tris"), a fully integrated, innovation-driven CNS company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), and a pipeline of treatments for pain, addiction, spasticity and narcolepsy, today announced that it has acquired rights to TRN-261 a non-opioid drug candidate that Tris intends to develop for multiple indications within acute and chronic pain.

Quick answer

Tris Pharma is acquiring Drug Candidate, announced December 7, 2022. Tris Pharma is based in Monmouth Junction, New Jersey, United States.

How much did Tris Pharma pay for Drug Candidate?
The deal value was not disclosed.
What does Tris Pharma do?
Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than..
Where are Tris Pharma and Drug Candidate based?
Tris Pharma is based in Monmouth Junction, New Jersey, United States.
Who are the decision-makers at Tris Pharma?
Fundz holds 1 contact at Tris Pharma. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Other recent acquisitions in Healthcare and Pharmaceutical Manufacturing

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at Tris Pharma, and when

When Tris Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Tris Pharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Tris Pharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Tris Pharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Tris Pharma

Location

Monmouth Junction, New Jersey, United States

About

Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than 150 U.S. and International patents including applications. We market several branded and generic products in the U.S; license our products in the U.S. and international markets and we have a robust pipeline of innovative products, that employ our proprietary science and technology, to meet patients’ needs in neuroscience and other therapeutic categories.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Tris Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Franchesca
Likely contact at this company
••••••••@••••••••

See Franchesca's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Tris Pharma's next move

Learn about Strategic plan

Frequently asked

Who acquired Drug Candidate?

Drug Candidate was acquired by Tris Pharma, based in Monmouth Junction. The deal was reported on December 7, 2022. Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Tris Pharma is privately held and operates in Healthcare.

When did Tris Pharma acquire Drug Candidate?

Tris Pharma's acquisition of Drug Candidate was reported on December 7, 2022. Tris Pharma, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Drug Candidate do?

Drug Candidate is the company acquired in this transaction. It is privately held.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.